For Immediate Release: July 14, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, […]

Office of Communications10001 New Hampshire AveHillandale Building, 4th FlSilver Spring, MD 20993 Toll Free (855) 543-3784 (301) 796-3400 Hours Available CDER Division of Drug Information

Providing information on proper drug use, safety, and storage Content current as of: 07/13/2023 Regulated Product(s) Topic(s)

Applying for Membership on FDA Advisory Committees As part of the Food and Drug Administration’s (FDA’s) ongoing efforts to recruit qualified experts with minimal conflicts of […]

FDA approval summary: pembrolizumab for neoadjuvant and adjuvant treatment of patients with high-risk early- stage triple negative breast cancer. Shah M, Osgood CL, Amatya AK, Fiero […]

Submit Comments by 09/12/2023 Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the FDA considers your comment […]

For Immediate Release: July 13, 2023 Today, the U.S. Food and Drug Administration approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy— the first daily […]

NCTR’s annual report summarizes the key accomplishments for each research division for the reported year. The report includes ongoing research project information, research collaboration highlights, and […]

Product: Drugs Recipient: Earthley Wellness dba Modern Alternative Mama LLC 240 Outerbelt Street, Suite #8Columbus, OH 43213United States Issuing Office: Center for Drug Evaluation and Research […]